TCRαβ-depleted and CD19-depleted progenitor cell graft

This refers to a specialized hematopoietic stem cell graft used in allogeneic transplantation, specifically a **TCRαβ-depleted and CD19-depleted progenitor cell graft**. Developed and utilized by **St. Jude Children's Research Hospital**, this graft is prepared from a family donor (typically haploidentical) using the **CliniMACS** system. The ex vivo processing involves the selective depletion of **αβ+ T cells** to minimize the risk of graft-versus-host disease (GVHD) and **CD19+ B cells** to prevent post-transplant Epstein-Barr virus-associated lymphoproliferative disease (EBV-LPD). The resulting product is enriched with **CD34+ hematopoietic stem cells**, **NK cells**, and **γδ+ T cells**, which provide hematopoietic reconstitution and potential graft-versus-leukemia (GVL) effects. This approach is primarily investigated for high-risk hematologic malignancies, including **acute lymphoblastic leukemia (ALL)**, **acute myeloid leukemia (AML)**, and **myelodysplastic syndromes (MDS)**, often as part of a regimen that includes post-transplant memory T-cell infusions and targeted agents like blinatumomab.

Other names

CD19+TCRα/β+TCRαβ/CD19-depleted graftCD19-depleted progenitor cellsCD-19-depleted progenitor cellsCD 19-depleted progenitor cellsTCRαβ-depleted progenitor cell graft